» Articles » PMID: 38180750

The Potential Value of the Purinergic Pathway in the Prognostic Assessment and Clinical Application of Kidney Renal Clear Cell Carcinoma

Overview
Specialty Geriatrics
Date 2024 Jan 5
PMID 38180750
Authors
Affiliations
Soon will be listed here.
Abstract

The Purinergic pathway is involved in a variety of important physiological processes in living organisms, and previous studies have shown that aberrant expression of the Purinergic pathway may contribute to the development of a variety of cancers, including kidney renal clear cell carcinoma (KIRC). The aim of this study was to delve into the Purinergic pathway in KIRC and to investigate its potential significance in prognostic assessment and clinical treatment. 33 genes associated with the Purinergic pathway were selected for pan-cancer analysis. Cluster analysis, targeted drug sensitivity analysis and immune cell infiltration analysis were applied to explore the mechanism of Purinergic pathway in KIRC. Using the machine learning process, we found that combining the Lasso+survivalSVM algorithm worked well for predicting survival accuracy in KIRC. We used LASSO regression to pinpoint nine Purinergic genes closely linked to KIRC, using them to create a survival model for KIRC. ROC survival curve was analyzed, and this survival model could effectively predict the survival rate of KIRC patients in the next 5, 7 and 10 years. Further univariate and multivariate Cox regression analyses revealed that age, grading, staging, and risk scores of KIRC patients were significantly associated with their prognostic survival and were identified as independent risk factors for prognosis. The nomogram tool developed through this study can help physicians accurately assess patient prognosis and provide guidance for developing treatment plans. The results of this study may bring new ideas for optimizing the prognostic assessment and therapeutic approaches for KIRC patients.

Citing Articles

Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing.

Chen J, Yuan Q, Guan H, Cui Y, Fu C, Wei T Front Immunol. 2024; 15:1461424.

PMID: 39346916 PMC: 11427318. DOI: 10.3389/fimmu.2024.1461424.


Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics.

Liu J, Yuan Q, Chen X, Yang Y, Xie T, Zhang Y Sci Rep. 2024; 14(1):17650.

PMID: 39085301 PMC: 11291735. DOI: 10.1038/s41598-024-68385-9.

References
1.
Liu D, Yang X, Wu X . Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma. Front Immunol. 2021; 12:663495. PMC: 8134682. DOI: 10.3389/fimmu.2021.663495. View

2.
Li W, Qiu Y, Zhang H, Liu Y, You J, Tian X . P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer. 2013; 109(6):1666-75. PMC: 3776994. DOI: 10.1038/bjc.2013.484. View

3.
Burnstock G . Introduction to Purinergic Signaling. Methods Mol Biol. 2019; 2041:1-15. DOI: 10.1007/978-1-4939-9717-6_1. View

4.
Asao T, Takahashi F, Takahashi K . Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig. 2018; 57(1):20-26. DOI: 10.1016/j.resinv.2018.09.001. View

5.
Lin X, Wang Z, Xue G, Qin X, Wu J, Zhang G . ADORA1 is a diagnostic-related biomarker and correlated with immune infiltrates in papillary thyroid carcinoma. J Cancer. 2021; 12(13):3997-4010. PMC: 8176250. DOI: 10.7150/jca.50743. View